Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression

ObjectiveTo explore the efficacy of c in the multiline treatment of late-stage lung adenocarcinoma with Her-2 overexpression and epidermal growth factor receptor (EGFR) mutations.MethodsWe summarize the diagnosis and treatment of a female patient with EGFR 21L858R mutation combined with Her-2 overex...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Meiling Lan, Tianyun Wang, Diexiao Luo, Yan Chen, Wei Liang, Rui Kong, Qichao Xie
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-12-01
coleção:	Frontiers in Oncology
Assuntos:	HER-2 overexpression epidermal growth factor receptor lung adenocarcinoma disitamab vedotin efficacy multiline treatment
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1472545/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!